Swedish Orphan Biovitrum AB (publ) (SOBI)
Free
No email, no account, no signup.
Pulling latest news for Swedish Orphan Biovitrum AB (publ)…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report – Signal
HOLD
Sentiment
10/10
Risk
5/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Buy express analysis –
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Sentiment improves on a clear Phase 3 clinical win (REDUCE 2), increasing perceived probability of value creation in the gout program and adding a nearer-term data readout ahead of REDUCE 1 later in 2026.
Exchange
Nasdaq Stockholm
Type
Biotech
Sector
Rare disease pharmaceuticals
Market Cap
$14.1B
Market sentiment
Sentiment improves on a clear Phase 3 clinical win (REDUCE 2), increasing perceived probability of value creation in the gout program and adding a nearer-term data readout ahead of REDUCE 1 later in 2026.
Why HOLD ?
The Q1 report is now out and was strong (revenue/EBITA beat and continued mix shift toward the strategic portfolio), reducing the need to stay in a "review" stance. However, the Arthrosi deal increases leverage and integration/execution risk, so the base call shifts to hold while monitoring leverage, margins and launch momentum into Q2.
- Hold; consider selectively adding on weakness if Q2 confirms continued CER growth and net debt/EBITDA stabilises or improves post-Arthrosi.
Recent News
- Since 2026-04-29: On 2026-05-06 Sobi held its AGM with routine resolutions. On 2026-05-21 Sobi reported positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad (AR882) in gout, meeting the primary endpoint (lower sUA at 6 months vs placebo) with tolerability consistent with prior studies; more detailed data are expected at a scientific congress in Q4 2026. No new equity issuance, major M&A, or major regulatory decisions were identified in the period.
Bull case
- The **Q1 report (28 Apr)** could confirm continued strong sales and margins.
- Positive momentum after **upgraded outlook** and a strong 2025.
Unlock to read more →
Bear case
- **Integration and financing costs** from Arthrosi may weigh near term.
Unlock to read more →
Catalysts
16 Jul 2026 — Q2 2026 report (Jan–Jun)
Dilution Risk
Assessment: Low
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Swedish Orphan Biovitrum AB (publ) – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
Full analysis at introductory pricing — 7-day money-back guarantee.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.